Business
Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity
Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces oral and poster presentations on preliminary studies of ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, will be presented at the 32nd European Congress On Obesity (ECO 2025) in Malaga, Spain.
About this update from Ascletis Pharma, Inc.
[{"type":"text","content":"HONG KONG, May 6, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces oral and poster presentations on preliminary studies of ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, will be presented at the 32nd European Congress On Obesity (ECO 2025) in Malaga, Spain.","length":333,"tagName":"p"},{"type":"text","content":"Oral Presentation DetailsTitle: ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO MiceAbstract Category/Topic: Obesity Management and Intervention » Emerging treatmentsAbstract Number: 0254Session: T1 Abstract Session: Novel Drugs. The Seeds for the Future Are HereSession Date and Time: 11:30-13:00, 13 May 2025 (Malaga Time), 17:30-19:00, 13 May 2025 (Beijing Time)Presenter: Jinzi Jason Wu","length":509,"tagName":"p"},{"type":"text","content":"Poster (Guided Poster) Presentation DetailsTitle: ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose StudyAbstract Number: 0816Abstract Category/Topic: Obesity Management and Intervention » Emerging treatmentsSession: Track Specific Poster Networking SessionSession Date and Time: 18:00-19:10, 13 May 2025 (Malaga Time), 00:00-01:10, 14 May 2025 (Beijing Time)Presenter: Jinzi Jason Wu","length":463,"tagName":"p"},{"type":"text","content":"About ASC47 ","length":11,"tagName":"p"},{"type":"text","content":"ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Topline data from its Phase Ib single subcutaneous injection studies in Australia in participants with elevated low-density lipoprotein cholesterol (LDL-C) (NCT06427590) have been released. The U.S. Investigational New Drug (IND) application for ASC47 in combination with semaglutide for the treatment of obesity has been cleared by U.S. Food and Drug Administration (FDA).","length":726,"tagName":"p"},{"type":"text","content":"About European Congress on Obesity","length":34,"tagName":"p...